Annovis Bio, Inc. (ANVS) Stock Price
ANVSStock
$1.72−25.86%52W
Market Cap$73.28M
P/E—
PEG Ratio—
Div yield—
Beta1.18
ANVS Share Price Chart
Favorite Metrics
Price vs S&P 500 (26W)-47.75%
Price vs S&P 500 (4W)-1.54%
VGM Score36.55
ANVS Earnings Surprise History
| Quarter | Report date | EPS estimate | EPS actual | Surprise |
|---|---|---|---|---|
| Q2 2026 | -$0.46 | -$0.40 | +13.04%(+$0.06) | |
| Q1 2026 | -$0.35 | -$0.63 | -80.00%(-$0.28) | |
| Q4 2025 | -$0.30 | -$0.39 | -30.00%(-$0.09) | |
| Q3 2025 | -$0.37 | -$0.37 | +0.00%(+$0.00) | |
| Q2 2025 | -$0.39 | -$0.32 | +17.95%(+$0.07) |
ANVS Analyst Recommendations
May 2026
Jun 2026
Jul 2026
Aug 2026
4.10
4.13
4.13
4.11
Industry Peers — Pharmaceuticals(570)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
ANVSAnnovis Bio, Inc. | — | — | D | $1.72 |
| LLYEli Lilly & Co. | D | B | C | $1174.61 |
| JNJJohnson & Johnson | D | C | B | $268.04 |
| ABBVABBVIE INC. | D | C | B | $255.48 |
| MRKMerck & Co., Inc. | D | C | B | $148.35 |
| NVSNovartis AG | C | C | C | $153.81 |
| AZNAstraZeneca PLC | C | B | C | $162.70 |
| NVONovo-Nordisk A/S | B | C | C | $45.61 |
| ABTAbbott Laboratories | C | C | C | $112.47 |
| PFEPfizer Inc. | C | D | B | $27.96 |
| VRTXVertex Pharmaceuticals Inc | D | C | B | $541.69 |
About Annovis Bio, Inc.
Annovis Bio is a clinical-stage biopharmaceutical company developing therapies for neurodegenerative diseases, primarily Alzheimer's and Parkinson's disease. Its pipeline includes Buntanetap for chronic neurodegeneration, ANVS405 for acute neurodegeneration, and ANVS301 for Alzheimer's disease.